4 ways to talk with vaccine skeptics

JULIE LEASK AND MARYKE STEFFEN | October 21, 2019

article image
Your neighbor is telling you about his new baby. He feels nervous about vaccinating, and says he's considering delaying Lucy's vaccines. Your mother's group is chatting about vaccines. One mother tells the group Jimmy isn't vaccinated, and she's using the Immune-Strengthening Diet instead. In a Facebook parenting group, someone comments we shouldn't trust pharmaceutical companies because they're covering up studies showing vaccines cause autism. These and similar scenarios may sound familiar. So what do you do when you're faced with someone who questions vaccination? Do you try to convince them to vaccinate? Do you ignore them? Or might something else work?

Spotlight

Hansyn Pharmaceutical Co., Ltd.

Hansyn Pharmaceutical Co., Ltd is a pharmaceutical company committed to increasing access to high-quality healthcare by development and manufacture of generic drugs of active pharmaceutical ingredients. Hansyn has cGMP veterinary drug production falicities and associated infra-structures producing veterinary ingredients such as Florfenicol and Thiamphenicol. Since 2012, Hansyn is entering human pharmaceutical area by investment of new cGMP multi-purpose plants (large scale plant, small scale plant, steroid plant), utility facilities, QC laboratories and R&D Centers, planned to be finished by 2013.

OTHER ARTICLES

Clinical Supply Availability & Speed to Study Start-Up

Article | March 26, 2020

If you’re part of a clinical study team racing a new product to commercialization, you likely live by these two simple rules: time is money, and the first one to market wins. But just because it’s simple doesn’t mean it’s easy. That ticking clock is background noise to the responsibilities of regulations, study protocols, supply chains, and patient recruitment — all the details that must be worked out before a study can even begin. The pressure is always there. The longer it takes for a study to start, the longer it takes to complete.

Read More

Pricing of drugs – at what cost?

Article | February 27, 2020

We go into a doctor’s office and leave with a diagnosis and a prescription. Next we stop by the pharmacy. In Germany, if your insurance is not private, you mostly don’t even know the price of your drug because it’s paid for directly by your insurance. You only notice the 5-10 Euros copay. But how is a drug priced in Germany? And (how) does data play a role in helping pharma secure an attractive price point? Let’s fast forward directly to the launch of a new drug. At the time of launch, the pharmaceutical company has to present patient level evidence of the drug’s added value compared to existing comparative therapies. In the first year, however, the drug’s price can be defined freely by the company.

Read More

What do you have to lose taking hydroxychloroquine for coronavirus? Potentially your life

Article | April 10, 2020

The president and some of his close advisors — desperate for a COVID-19 cure — are asking “What do you have to lose?” by taking hydroxychloroquine (HCQ), a strong medication never adequately tested for efficacy or safety in COVID-19 patients. The correct answer to the president’s question, which he doesn’t seem to want to hear, is that we have our lives to lose. The president acknowledges “I’m not a doctor” but this raises the question “What do doctors know about the drug recommended by the president? Most doctors are aware that HCQ can be effective for patients with malaria, arthritis or lupus. If they were to follow the president’s suggestion and prescribe it for COVID-19 patients, they would also like to know that it will benefit some of those patients, at least.

Read More

Clinical Development Risks and Issues in a COVID-19 World

Article | March 20, 2020

Global clinical guidelines have shifted the industry toward risk-based approaches for the planning and execution of clinical trials. The ICH’s guidelines for Good Clinical Practice state that sponsors should evaluate identified risks against existing risk controls by considering “the likelihood of errors occurring, the extent to which such errors would be detectable, and the impact of such errors on human subject protection and reliability of trial results” (ICH E6 R2).

Read More

Spotlight

Hansyn Pharmaceutical Co., Ltd.

Hansyn Pharmaceutical Co., Ltd is a pharmaceutical company committed to increasing access to high-quality healthcare by development and manufacture of generic drugs of active pharmaceutical ingredients. Hansyn has cGMP veterinary drug production falicities and associated infra-structures producing veterinary ingredients such as Florfenicol and Thiamphenicol. Since 2012, Hansyn is entering human pharmaceutical area by investment of new cGMP multi-purpose plants (large scale plant, small scale plant, steroid plant), utility facilities, QC laboratories and R&D Centers, planned to be finished by 2013.

Events